Matrix metalloproteinase 3 polymorphism: A predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma

Treatment of head and neck cancer often associates different therapeutic modalities, including surgery, radiotherapy, and chemotherapy. In an attempt to optimize therapeutics, the identification of molecular markers linked to response to chemotherapy remains important. Recently, the involvement of m...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2004-04, Vol.10 (8), p.2594-2599
Hauptverfasser:	BLONS, Hélène, GAD, Sophie, ZINZINDOHOUE, Franck, MANIERE, Isabelle, BEAUREGARD, Janie, TREGOUET, David, BRASNU, Daniel, BEAUNE, Philippe, LACCOURREYE, Ollivier, LAURENT-PUIG, Pierre
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Alleles Antineoplastic agents Biological and medical sciences Carcinoma, Squamous Cell - drug therapy Chemotherapy, Adjuvant Cisplatin - therapeutic use Fas Ligand Protein fas Receptor - metabolism Female Fluorouracil - therapeutic use Genes, p53 Genotype Head and Neck Neoplasms - drug therapy Humans Male Matrix Metalloproteinase 1 - genetics Matrix Metalloproteinase 3 - genetics Matrix Metalloproteinase 7 - genetics Medical sciences Membrane Glycoproteins - metabolism Middle Aged Multivariate Analysis Mutation Odds Ratio Pharmacology. Drug treatments Polymorphism, Genetic Prognosis Prospective Studies Sex Factors Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!